KPTI / Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Misses Revenue Estimates

Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Ric more_horizontal

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares more_horizontal

Karyopharm Therapeutics (NASDAQ: KPTI ) stock is climbing higher on Tuesday after getting fast-track designation for its myelofibrosis treatment. The more_horizontal

Karyopharm Therapeutics (KPTI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank # more_horizontal

Karyopharm Therapeutics, Inc. (NASDAQ:KPTI ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard more_horizontal

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares more_horizontal

Shares are down 50% over the past year as fierce competition in the multiple myeloma space negatively impacts Xpovio's growth prospects. However, ther more_horizontal

Karyopharm Therapeutics, Inc. (NASDAQ:KPTI ) Q4 2022 Earnings Conference Call February 15, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR R more_horizontal